Published in Med Decis Making on December 09, 1999
Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol (2009) 1.04
Fundamental principles of conducting a surgery economic analysis study. Plast Reconstr Surg (2010) 0.89
Economic evaluation of task-shifting approaches to the dispensing of anti-retroviral therapy. Hum Resour Health (2012) 0.87
Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure. PLoS One (2007) 0.84
Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU. Ann Hematol (2015) 0.82
A 5-Year Cost-Effectiveness Analysis of Silicone Metacarpophalangeal Arthroplasty in Patients with Rheumatoid Arthritis. Plast Reconstr Surg (2015) 0.79
Evaluating Cost-effectiveness of Interventions That Affect Fertility and Childbearing: How Health Effects Are Measured Matters. Med Decis Making (2015) 0.77
Realistic rigor in cost-effectiveness methods. Med Decis Making (1999) 0.76
Modelling the cost effectiveness of disease-modifying treatments for multiple sclerosis: issues to consider. Pharmacoeconomics (2013) 0.76
Improving the Panel's recommendations. Med Decis Making (1999) 0.75
Cost-effectiveness of lung cancer screening and treatment methods: a systematic review of systematic reviews. BMC Health Serv Res (2017) 0.75
Theoretically correct cost-effectiveness analysis. Med Decis Making (1999) 0.75
Modeling lifetime costs and health outcomes attributable to secondhand smoke exposure at home among Korean adult women. BMJ Open (2017) 0.75
Swedish population health-related quality of life results using the EQ-5D. Qual Life Res (2001) 2.87
Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros (2008) 2.56
Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S) Eur Heart J (1996) 2.31
Is misoprostol cost-effective in the prevention of nonsteroidal anti-inflammatory drug-induced gastropathy in patients with chronic arthritis? A review of conflicting economic evaluations. Arch Intern Med (1994) 2.25
Health-related quality of life by disease and socio-economic group in the general population in Sweden. Health Policy (2001) 1.89
An experimental test of a theoretical foundation for rating-scale valuations. Med Decis Making (1997) 1.66
Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus; results from the DIGAMI study. Eur Heart J (2000) 1.60
The impact of hormone replacement therapy on quality of life and willingness to pay. Br J Obstet Gynaecol (1997) 1.58
Predictors of deterioration of lung function in cystic fibrosis. Pediatr Pulmonol (2002) 1.58
Exhaled carbon monoxide is not elevated in patients with asthma or cystic fibrosis. Eur Respir J (2002) 1.49
Interpretation of change scores in ordinal clinical scales and health status measures: the whole may not equal the sum of the parts. J Clin Epidemiol (1996) 1.44
Incorporating quality of life changes into economic evaluations of health care: an overview. Health Policy (1996) 1.42
The willingness to pay for in vitro fertilization: a pilot study using contingent valuation. Med Care (1994) 1.39
Hypothetical versus real willingness to pay in the health care sector: results from a field experiment. J Health Econ (2001) 1.30
The decision rules of cost-effectiveness analysis. Pharmacoeconomics (1996) 1.18
Genetic control of collagen-induced arthritis in a cross with NOD and C57BL/10 mice is dependent on gene regions encoding complement factor 5 and FcgammaRIIb and is not associated with loci controlling diabetes. Eur J Immunol (2001) 1.16
The relationship between health-state utilities and the SF-12 in a general population. Med Decis Making (1999) 1.15
Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol (1999) 1.13
The costs and effects of two different lipid intervention programmes in primary health care. J Intern Med (1995) 1.09
A note on confidence intervals in cost-effectiveness analysis. Int J Technol Assess Health Care (1998) 1.08
Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma. Ann Allergy Asthma Immunol (1998) 1.07
Some reflections on cost-effectiveness analysis. Health Econ (1998) 1.05
Perceptions and preferences of autologous blood donors. Transfusion (1998) 1.01
Urge incontinence. Quality of life and patients' valuation of symptom reduction. Pharmacoeconomics (1998) 0.99
The validity of QALYs: an experimental test of constant proportional tradeoff and utility independence. Med Decis Making (1997) 0.99
Standard gamble, time trade-off and rating scale: experimental results on the ranking properties of QALYs. J Health Econ (1997) 0.97
The cost-effectiveness of a cardiovascular risk reduction program in general practice. Health Policy (1997) 0.97
Willingness to pay for reductions in angina pectoris attacks. Med Decis Making (1996) 0.97
Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol (2001) 0.95
An experimental test of question framing in health state utility assessment. Health Policy (1998) 0.93
Influence of CD4 or CD8 deficiency on collagen-induced arthritis. Immunology (2001) 0.91
Guidelines for the management of pregnancy in women with cystic fibrosis. J Cyst Fibros (2007) 0.91
A comparison of patient and social tariff values derived from the time trade-off method. Health Econ (1999) 0.91
Income-related inequality in life-years and quality-adjusted life-years. J Health Econ (2000) 0.91
A note on validating Wagstaff and van Doorslaer's health measure in the analysis of inequalities in health. J Health Econ (1999) 0.91
Effects of user charges on the use of prescription medicines in different socio-economic groups. Health Policy (1998) 0.87
Economic evaluation in healthcare. A brief history and future directions. Pharmacoeconomics (1996) 0.87
Cost-effectiveness analysis and capital costs. Soc Sci Med (1998) 0.84
Patients' willingness to pay for autologous blood donation. Health Policy (1997) 0.83
Use of contingent valuation to place a monetary value on pharmacy services: an overview and review of the literature. Clin Ther (1999) 0.81
Valuation of health changes with the contingent valuation method: a test of scope and question order effects. Health Econ (1997) 0.81
New estimates of the demand for health: results based on a categorical health measure and Swedish micro data. Soc Sci Med (1999) 0.80
Genetic heterogeneity of autoimmune disorders in the nonobese diabetic mouse. Scand J Immunol (2003) 0.80
The effect of changes in treatment patterns on drug expenditure. Pharmacoeconomics (1998) 0.79
Composition of nasal airway surface liquid in cystic fibrosis and other airway diseases determined by X-ray microanalysis. Microsc Res Tech (2006) 0.79
A computer model to analyze the cost-effectiveness of hormone replacement therapy. Int J Technol Assess Health Care (1999) 0.79
Three common CFTR mutations should be included in a neonatal screening programme for cystic fibrosis in Sweden. Clin Genet (1999) 0.78
From principle to public policy: using cost-effectiveness analysis. Health Aff (Millwood) (1994) 0.77
Signal variance electrocardiogram: a test for early detection of myocardial involvement in cystic fibrosis? Clin Sci (Lond) (1994) 0.77
Cost-benefit aspects of treatment of hypertension in the elderly. Blood Press Suppl (1995) 0.76
The impact of user charges on the consumption of drugs. Empirical evidence and economic implications. Pharmacoeconomics (1996) 0.75
Cost effectiveness and allocation of therapies in a treating population. Pharmacoeconomics (1997) 0.75
Comment on "Dealing with discounting". Int J Technol Assess Health Care (1991) 0.75
Cost-benefit analysis of lipid lowering therapy. Eur Heart J (1997) 0.75
[The 4S study is analysed. Cholesterol reduction is cost-efficient]. Lakartidningen (1997) 0.75
Registered Replication Report: Rand, Greene, and Nowak (2012). Perspect Psychol Sci (2017) 0.75
Price indices of drugs and the switching to new drugs. Two empirical examples. Pharmacoeconomics (1998) 0.75
[Should patients with cystic fibrosis become parents? Patient's own choice following matter-of-fact information is significant]. Lakartidningen (1999) 0.75
Contingent valuation with an open-ended follow-up question: a test of scope effects. Health Econ (1998) 0.75
Use of misoprostol in the elderly: is the expense justified? Drugs Aging (1996) 0.75
Saving lives in the present versus saving lives in the future--is there a framing effect? J Risk Uncertain (1997) 0.75
[Exercise is effective in back pain]. Lakartidningen (1994) 0.75
Value for money? A contingent valuation study of the optimal size of the Swedish health care budget. Health Policy (1995) 0.75
The impact of risk information on patients' willingness to pay for autologous blood donation. Med Care (1998) 0.75
Cost benefit of treating hypertension. Clin Exp Hypertens (1999) 0.75
Drug expenditure and new drug introductions: the Swedish experience. Pharmacoeconomics (1993) 0.75